BerGenBio ASA skal på børs ved hjelp av ABG Sundal Collier, DNB og Arctic Securities. BerGenBio er et onkologisk bioteknologiselskap i klinisk fase som utvikler ’first-in-class’ legemidler mot nye medikamentmål (drug targets) som driver aggressiv kreft. Selskapet har en unik og ledende forståelse av funksjonen og rollen til Axl, en reseptor av typen tyrosin kinase. Selskapet ser for seg å hente nok kapital denne runden til å være velfinansiert et stykke ut i 2019 og planlegger å få BGB324 gjennom fase II og BGB149 gjennom fase 1 i denne perioden. Medikamentene vil brukes sammen med andre medisiner og behandlinger for å øke effektiviteten av disse når kroppen ikke lengre klare å kjempe mot kreftcellene med disse medisinene.

BerGenBIo




Tegningsperiode: 29.03.2017 til 04.04.2017 kl.12:00.
Kursintervall: 25 kr.
Ingen retail rabatt
Minste tegning: 10.500 kr

Selskapet er i en tidlig fase og selv om produktene deres har gitt lovende resultater i testene som er gjort frem til nå er det fremdeles et godt stykke frem til kommersialisering. Det er stor sannsynlighet for at det vil komme nye emisjoner fra 2019 og fremover hvis de ikke inngår avtaler med store legemiddelaktører slik Algeta i sin tid gjorde med Bayer. Med en lovende produktportefølje følges BerGenBio tett av de store aktørene. De store aktørene vet at en overtagelse vil koste eksponensielt mye mer jo lengre BerGenBio er kommet i testingen og jo bedre resultatene i disse testene er. Og selskaper som har produkter som blir mer effektive ved bruk sammen med BerGenBio sine produkter vil ha stor interesse av å ta kontroll over prisingen av hele behandlingen av pasientene. Det er derfor stor sannsynlighet for at det kommer et bud på BerGenBio om produktene deres viser seg å være så gode som de mener at det er i denne tidlige fasen.


Om selskapet:

BerGenBio is a clinical stage oncology biotech company developing first- in-class therapeutics against novel drug targets that drive aggressive cancers. The Company has a deep and leading understanding of the role and function of Axl, a drug target of the class receptor tyrosine kinase. Axl is generally accepted as a driver of many of the hallmarks of aggressive cancer and is also an essential mediator of cellular plasticity through the pathway known as epithelial-mesenchymal-transition (“EMT”). The Companys primary aim, either alone or in collaboration with a partner, is to develop and commercialise its lead product BGB324 through to marketing approval by the regulatory agencies and subsequent commercialisation.

The Company’s most advanced anti-cancer drug candidate is BGB324, which is a first-in-class highly selective, orally bioavailable inhibitor of Axl and the only selective Axl inhibitor undergoing clinical trials. BerGenBio is currently sponsoring ongoing clinical trials with BGB324 as a single agent and in combination with standard of care drugs in patients with acute myeloid leukaemia (“AML”), myelodysplastic syndrome (MDS) and non-small cell lung cancer (NSCLC). In addition, BerGenBio anticipates within H1 2017, the commencement of two additional Phase II clinical trials with BGB324 administered in combination with KeytrudaTM in patients with NSCLC and triple negative breast cancer (TNBC). BerGenBio is also actively working on the development of a companion diagnostics tool to identify patients who may specifically benefit from treatment with BGB324. Initial clinical data has indicated that those patients who have the activated form of Axl are more likely to respond to treatment with BGB324.

BerGenBio has leveraged its leading position in Axl biology to establish international partnerships; (i) with ADC Therapeutics S.a.r.l. (ADCT), a Swiss biotech company, to whom the Company has licensed preclinical Axl antibodies for the development of an antibody-drug conjugate (ADC) and (ii) Merck Sharp & Dohme B.V. (MSD), a global pharmaceutical company, who will supply its immune checkpoint inhibitor Keytuda for combination clinical studies in patients with lung cancer and TNBC.

BerGenBio’s founding research was undertaken at the University of Bergen, and in 2007 the Company was established by Bergen Teknologioverføring AS (the technology transfer office of the University of Bergen (“UiB”)), UniResearch AS (the investment holding company of UiB), Prof. James Lorens and Dr. David Micklem. The Company maintains its administrative and research offices in Bergen whilst its clinical development functions are led from its office in Oxford in the United Kingdom. The primary aim of the Company is to complete regulatory trials of BGB324 in a subset of patients with AML/MDS, whilst simultaneously pursuing further clinclal trials to determine the utility of BGB324 in patients with more common cancers such as NSCLC and TNBC.

Nettsiden til selskapet

Prospekt

Tegning via VPS

Write us

Find us at the office

Darmofal- Broderick street no. 11, 88736 Vatican City, Vatican City

Give us a ring

Meadow Hipsley
+90 293 316 242
Mon - Fri, 8:00-14:00

Join us